Related Experiment Video
Updated: Jul 13, 2025

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
The crosstalk between non-coding RNA polymorphisms and resistance to lung cancer therapies
Samaneh Mollazadeh1, Negar Abdolahzadeh2, Meysam Moghbeli3
1Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran.
Abstract:
Lung cancer (LC) is one of the most common cancer-related mortality in the world. Even with intensive multimodality therapies, lung cancer has a poor prognosis and a high morbidity rate. This review focused on the role of non-coding RNA polymorphisms such as lncRNAs and miRNAs in the resistance to LC therapies, which could open promising avenue for better therapeutic response. Of note, there is currently no valid biomarker to predict lung cancer sensitivity in patients during treatment. Since genetic variations cause many challenges in treating patients, genotyping of known polymorphisms must be thoroughly explored to find desirable treatment platforms. With this knowledge, individualized treatments could become more possible in management of LC.
Related Concept Videos
lncRNA - Long Non-coding RNAs
Treatment Resistant Cancers
MicroRNAs
Single Nucleotide Polymorphisms-SNPs
RNA Splicing
Non-LTR Retrotransposons

